LLY

1,080.48

+0.26%↑

JNJ

231.95

+0.48%↑

ABBV

215.45

+1.3%↑

UNH

381.71

+0.93%↑

AZN

186.94

-0.34%↓

LLY

1,080.48

+0.26%↑

JNJ

231.95

+0.48%↑

ABBV

215.45

+1.3%↑

UNH

381.71

+0.93%↑

AZN

186.94

-0.34%↓

LLY

1,080.48

+0.26%↑

JNJ

231.95

+0.48%↑

ABBV

215.45

+1.3%↑

UNH

381.71

+0.93%↑

AZN

186.94

-0.34%↓

LLY

1,080.48

+0.26%↑

JNJ

231.95

+0.48%↑

ABBV

215.45

+1.3%↑

UNH

381.71

+0.93%↑

AZN

186.94

-0.34%↓

LLY

1,080.48

+0.26%↑

JNJ

231.95

+0.48%↑

ABBV

215.45

+1.3%↑

UNH

381.71

+0.93%↑

AZN

186.94

-0.34%↓

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Abierto

SectorSanidad

10.4 -6.31

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

10.3

Máximo

11.14

Métricas clave
By Trading Economics
Ingresos	7.7M -73M
Ventas	929K 18M
BPA	-0.828
Margen de beneficios	-401.495
Empleados	260
EBITDA	7.4M -78M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+149.87% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	159M 1B
Apertura anterior	16.71
Cierre anterior	10.4

Noticias sobre sentimiento de mercado

By Acuity

19%

81%

26 / 344 Clasificación en Healthcare

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 may 2026, 16:52 UTC

Noticias de Eventos Importantes

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 may 2026, 23:57 UTC

Ganancias

Sociedad Quimica 1Q Rev $1.76B >SQM

26 may 2026, 23:57 UTC

Ganancias

Sociedad Quimica 1Q EPS $1.28 >SQM

26 may 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 may 2026, 21:54 UTC

Ganancias

Webco Industries 3Q EPS $11.61 >WEBC

26 may 2026, 21:54 UTC

Ganancias

Webco Industries 3Q Sales $179.6M >WEBC

26 may 2026, 21:48 UTC

Charlas de Mercado

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 may 2026, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

26 may 2026, 20:58 UTC

Adquisiciones, fusiones, absorciones

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

26 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

26 may 2026, 19:22 UTC

Charlas de Mercado

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 may 2026, 19:17 UTC

Charlas de Mercado

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 may 2026, 18:56 UTC

Charlas de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 may 2026, 18:03 UTC

Charlas de Mercado

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 may 2026, 17:42 UTC

Charlas de Mercado

Grains Await Fresh Trading Catalyst -- Market Talk

26 may 2026, 17:33 UTC

Charlas de Mercado

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 may 2026, 17:21 UTC

Charlas de Mercado

Canada Faces a Labor Market Squeeze -- Market Talk

26 may 2026, 16:52 UTC

Charlas de Mercado

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 may 2026, 16:43 UTC

Charlas de Mercado

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 may 2026, 16:24 UTC

Charlas de Mercado

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 may 2026, 16:21 UTC

Charlas de Mercado

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Auto & Transport Roundup: Market Talk

26 may 2026, 16:16 UTC

Charlas de Mercado

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 may 2026, 16:01 UTC

Charlas de Mercado

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 may 2026, 15:21 UTC

Charlas de Mercado

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

149.87% repunte

Estimación a 12 Meses

Media 28.11 USD 149.87%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

26 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.